Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

Amenis Bioscience Inc. has identified anthranilic acid derivatives acting as peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) and viral replication inhibitors reported to be useful for ...

National Science & Technology Development Agency (NSTDA) has described cordycepin derivatives acting as viral replication inhibitors reported to be useful for the treatment of viral infections.

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

Infection with cytomegalovirus (CMV) is extremely common, but the virus only becomes pathogenic when the immune system is weakened, by, for example, HIV or anti-rejection transplant immunosupressors.

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.